Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosis

Ther Drug Monit. 1993 Feb;15(1):52-9. doi: 10.1097/00007691-199302000-00010.

Abstract

The predictive performance of a dosage calculation method for the optimization of tobramycin therapy was studied retrospectively in 29 patients with cystic fibrosis. The dosage calculation method was based on a linear one-compartment open model. It used peak and trough serum concentrations of the aminoglycoside. Bias in the peak concentration was 0.20 mg/L and precision was 1.2 mg/L. Bias in the trough concentration was -0.06 mg/L and precision was 0.33 mg/L. The results were clinically satisfactory. Comparison with previously published results of the predictive performance of other dosage calculation methods showed that the method studied was at least as good.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aging / blood
  • Cystic Fibrosis / blood
  • Cystic Fibrosis / drug therapy*
  • Drug Administration Schedule
  • Drug Delivery Systems
  • Drug Monitoring / methods
  • Female
  • Humans
  • Male
  • Models, Biological
  • Predictive Value of Tests
  • Reproducibility of Results
  • Retrospective Studies
  • Tobramycin / administration & dosage*
  • Tobramycin / blood*

Substances

  • Tobramycin